Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
C4 Therapeutics ( (CCCC) ) has shared an announcement.
On May 12, 2026, C4 Therapeutics reported first-quarter 2026 results and highlighted clinical progress, including dosing first patients in its Phase 2 MOMENTUM trial and a Phase 1b trial combining cemsidomide, dexamethasone and elranatamab for multiple myeloma. The company is also planning a further Phase 1b trial in 2027 with approved multiple myeloma therapies, while presenting emerging cemsidomide data at major oncology meetings.
Management expanded C4’s strategic footprint by signing a new collaboration with Roche in April 2026 to develop degrader-antibody conjugates, receiving a $20 million upfront payment in May and winding down development of its EGFR L858R degrader CFT8919 outside Greater China. For the quarter, revenue declined to $6.2 million, net loss narrowed to $25.1 million, and a $268.3 million cash balance is expected to fund operations through the end of 2028, underscoring financial capacity to pursue its targeted protein degradation pipeline.
The most recent analyst rating on (CCCC) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.
Spark’s Take on CCCC Stock
According to Spark, TipRanks’ AI Analyst, CCCC is a Neutral.
The score is held back primarily by weak financial performance (deep losses, ongoing cash burn, and 2025 revenue falling to $0), partially offset by constructive technical momentum and positive corporate developments (expanded Roche deal and multi-year clinical strategy with runway to 2028). Valuation remains constrained by negative earnings and no dividend support.
To see Spark’s full report on CCCC stock, click here.
More about C4 Therapeutics
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation therapies for cancer, with a particular emphasis on multiple myeloma. Its lead investigational product, cemsidomide, is an orally bioavailable IKZF1/3 degrader being developed as a potentially foundational treatment across multiple lines of multiple myeloma care.
Average Trading Volume: 2,850,775
Technical Sentiment Signal: Hold
Current Market Cap: $287.9M
For a thorough assessment of CCCC stock, go to TipRanks’ Stock Analysis page.